FDA Targets 30 Compounded GLP-1 Sellers, Boosting Lilly as Market Heads to $137.4B
FDA sent 30 warning letters to telehealth firms for illicit compounded GLP-1 drugs marketed as alternatives to Lilly therapies, boosting branded sales. The GLP-1 market is projected to jump from $51.9B in 2024 to $137.4B by 2030, supporting growth prospects for Lilly’s Trulicity.
1. FDA Cracks Down on Compounded GLP-1 Products
The FDA issued 30 warning letters to telehealth and compounding pharmacies for false or misleading promotion of compounded GLP-1 formulations that compete with branded therapies. By targeting unauthorized compounders, the agency aims to curb unapproved versions and may drive patients towards established Lilly products like Trulicity and other GLP-1 treatments.
2. GLP-1 Market Set for Rapid Expansion
Analysts forecast the GLP-1 receptor agonist market to swell from $51.9 billion in 2024 to $137.4 billion by 2030, fueled by rising diabetes and obesity rates, new oral formulations and exploration into cardiovascular and liver disease applications. Lilly’s Trulicity, with its strong market share and clinical pipeline, is positioned to capture a significant portion of this growth trajectory.